Sunitinib
- Generic Name
- Sunitinib
- Brand Names
- Sutent, Sunitinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27FN4O2
- CAS Number
- 557795-19-4
- Unique Ingredient Identifier
- V99T50803M
- Background
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
- Indication
Sunitinib is indicated for the following conditions:
- Associated Conditions
- Gastrointestinal Stromal Tumor (GIST), Renal Cell Carcinoma (RCC), Renal Cell Carcinoma Recurrent, Unresectable, locally advanced Progressive Neuroendocrine Tumors of pancreatic origin, Unresectable, metastatic Progressive Neuroendocrine Tumors of pancreatic origin
- Associated Therapies
- -
Bevacizumab in Multiple Phase I Combinations
- Conditions
- Interventions
- First Posted Date
- 2007-10-15
- Last Posted Date
- 2020-06-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 343
- Registration Number
- NCT00543504
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2007-10-12
- Last Posted Date
- 2014-03-07
- Lead Sponsor
- AGO Study Group
- Target Recruit Count
- 73
- Registration Number
- NCT00543049
- Locations
- 🇩🇪
Malterser-Krankenhaus Bonn-Rhein/Sieg, Frauenklinik, Bonn, Germany
🇩🇪Universitätsklinikum Carl Gustav Carus, Klinik u. Poliklinik für Frauenheilkunde und Geburtshilfe, Dresden, Germany
🇩🇪Universitätsklinikum, Universitätsfrauenklinik, Ulm, Germany
Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer
- Conditions
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 92
- Registration Number
- NCT00541008
- Locations
- 🇫🇷
Hopital Saint Michel, Paris, France
🇫🇷CHU de la Timone, Marseille, France
🇫🇷Centre Paul Papin, Angers, France
Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
- Conditions
- Interventions
- First Posted Date
- 2007-09-28
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 17
- Registration Number
- NCT00537056
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2010-08-30
- Lead Sponsor
- Medical University Innsbruck
- Target Recruit Count
- 70
- Registration Number
- NCT00535379
- Locations
- 🇦🇹
LKH Feldkirch, Feldkirch, Austria
🇦🇹LNK Wagner-Jauregg, Linz, Austria
🇩🇪University Hospital of Bonn, Bonn, Nordrhein-Westfalen, Germany
Sunitinib in Treating Patients With Locally Advanced Bladder Cancer
- First Posted Date
- 2007-09-10
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT00526656
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer
- First Posted Date
- 2007-09-03
- Last Posted Date
- 2016-06-21
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 23
- Registration Number
- NCT00524186
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
- First Posted Date
- 2007-09-03
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 16
- Registration Number
- NCT00524316
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC
- Conditions
- Interventions
- First Posted Date
- 2007-08-29
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 10
- Registration Number
- NCT00522249
- Locations
- 🇺🇸
Baylor College of Medicine - Methodist Hospital, Houston, Texas, United States
Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2007-08-27
- Last Posted Date
- 2014-05-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00521092
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.